Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.40% Shs Outstand147.47M Perf Week2.53%
Market Cap13.84B Forward P/E- EPS next Y-1.93 Insider Trans-1.99% Shs Float147.14M Perf Month10.30%
Income-126.20M PEG- EPS next Q-0.60 Inst Own- Short Float3.00% Perf Quarter35.84%
Sales667.10M P/S20.74 EPS this Y-34.70% Inst Trans1.83% Short Ratio3.66 Perf Half Y46.08%
Book/sh10.26 P/B9.15 EPS next Y-91.40% ROA-5.40% Target Price102.47 Perf Year37.27%
Cash/sh4.52 P/C20.77 EPS next 5Y25.00% ROE-8.70% 52W Range55.04 - 96.36 Perf YTD33.39%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-2.61% Beta0.92
Dividend %- Quick Ratio4.20 Sales past 5Y13.10% Gross Margin83.70% 52W Low70.49% ATR3.26
Employees1341 Current Ratio5.20 Sales Q/Q29.10% Oper. Margin-23.30% RSI (14)62.49 Volatility3.99% 3.64%
OptionableYes Debt/Eq0.44 EPS Q/Q113.20% Profit Margin-18.90% Rel Volume1.46 Prev Close91.83
ShortableYes LT Debt/Eq0.44 EarningsOct 23 AMC Payout- Avg Volume1.21M Price93.84
Recom1.90 SMA204.53% SMA5012.50% SMA20035.17% Volume1,763,621 Change2.19%
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Sep-18-13Downgrade Stifel Buy → Hold
Jul-26-13Reiterated Stifel Buy $67 → $70
Apr-03-13Reiterated Barclays Overweight $54 → $70
Mar-20-13Reiterated RBC Capital Mkts Outperform $58 → $64
Mar-20-13Reiterated Deutsche Bank Hold $45 → $59
Feb-22-13Reiterated RBC Capital Mkts Outperform $55 → $58
Feb-01-13Reiterated UBS Buy $53 → $67
Jan-22-13Upgrade Stifel Nicolaus Hold → Buy $67
Nov-06-12Reiterated Barclays Overweight $46 → $54
Nov-06-12Downgrade Brean Capital Buy → Hold
Sep-28-12Reiterated Summer Street Research Buy $45 → $52
Aug-27-12Downgrade Deutsche Bank Buy → Hold $40 → $45
Dec-12-14 12:40PM  PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
Dec-10-14 12:32PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement EDGAR Online
08:01AM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome GlobeNewswire
08:00AM  FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B) GlobeNewswire
Dec-09-14 08:00AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York GlobeNewswire
Dec-07-14 04:00PM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome GlobeNewswire
Dec-05-14 06:00AM  Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet
Dec-03-14 05:24PM  Rare disease biotech deal CNBC
08:00AM  BioMarin to Host Analyst and Investor Day on December 10th in New York GlobeNewswire
06:00AM  Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES at TheStreet
Dec-02-14 08:21PM  Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners at TheStreet
07:07PM  Cramer Remix: The best stocks to own now at CNBC
06:12PM  Cramer: Cut the line on bottom fishing! at CNBC
05:18PM  RBC's biotech picks: CELG, BMRN & VRTX CNBC
05:00PM  7 Biotech stocks to buy now CNBC
04:53AM  Transforming Biotech Coal to Gold: A Look At Puma, BioMarin and Cellceutix Company Spotlight
Dec-01-14 08:05AM  KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors PR Newswire
Nov-28-14 08:34AM  The Zacks Analyst Blog Highlights: BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex Zacks
Nov-26-14 04:47PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-24-14 05:24PM  It was another slow, low volume, lackluster trading session Yahoo Finance Blogs
04:49PM  US STOCKS-S&P 500 ticks up to record on central bank bets Reuters
04:37PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
03:58PM  Barbarian At The Gate: Biomarin Pharmaceutical (BMRN) at TheStreet
03:19PM  US STOCKS-Wall St up on central bank bets, deals support Reuters
12:34PM  US STOCKS-Wall St hits new records, but telecom weighs on Dow Reuters
12:20PM  BioMarin's Prosensa Buy: A 'Courageous' Acquisition? at Barrons.com
11:18AM  US STOCKS-Wall St hits new records, boosted by cyclicals Reuters
10:50AM  BioMarin to Pay Up to $840 Million for Prosensa at The Wall Street Journal
10:24AM  In Risky Bet, BioMarin Acquires Prosensa for as Much as $840 Million at BusinessWeek
10:22AM  BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
10:04AM  US STOCKS-Wall St surges to new records, boosted by cyclicals Reuters
09:19AM  Stock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily
08:52AM  US STOCKS-Futures point to higher open on merger activity Reuters
08:14AM  US STOCKS-Futures rise, boosted by merger activity Reuters
07:59AM  Early Movers: UTX, VZ, TSLA, LGA, RNA & more at CNBC
07:35AM  BioMarin Pharma offers about $680M for Prosensa AP
07:14AM  US STOCKS-Futures higher, building on recent gains Reuters
06:58AM  November 24 Premarket Briefing: 10 Things You Should Know TheStreet
06:45AM  BioMarin Buys Muscular Dystrophy Treatment Developer Prosensa at Bloomberg
06:34AM  BioMarin Expands Reach By Buying Prosensa for Up to $840 Million at TheStreet
06:34AM  BioMarin Acquires Prosensa in Deal Valued Up to $840 Million at TheStreet
06:24AM  BioMarin to buy Prosensa in $840 mln deal Reuters
06:00AM  BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio GlobeNewswire
Nov-21-14 10:03AM  Fighting kids' cancer, one voucher at a time at CNBC
06:00AM  How to get cancer drugs to kids: A mother's take at CNBC
Nov-19-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
Nov-14-14 02:30PM  Street Talk: HOG, LULU, BMRN, MDVN & TRS CNBC -5.77%
Nov-12-14 04:30PM  Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? Zacks
Nov-10-14 04:28PM  Major averages start the week where they left offhigher Yahoo Finance Blogs
08:45AM  Top Analyst Upgrades and Downgrades: BioMarin, BP, Genworth, Petrobras, Target and More at 24/7 Wall St.
Nov-04-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08:00AM  Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference GlobeNewswire
Nov-03-14 04:31PM  It was a lackluster trading session for U.S. equities Yahoo Finance Blogs
02:30PM  Street Talk: Downgrade for Deans CNBC
09:55AM  Cramer's Stop Trading: Stratasys & BioMarin CNBC
Oct-30-14 08:08PM  10-Q for BioMarin Pharmaceutical, Inc. Company Spotlight
Oct-29-14 07:55AM  Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? Zacks
Oct-28-14 03:10PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-27-14 02:12AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% Zacks
Oct-24-14 01:00PM  BioMarin Q3 Loss Narrower than Expected, View Raised Zacks +8.03%
Oct-23-14 04:57PM  BioMarin beats 3Q profit forecasts AP
04:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Announces Third Quarter 2014 Financial Results GlobeNewswire
07:07AM  Q3 2014 Biomarin Pharmaceutical Inc Earnings Release - After Market Close CCBN
Oct-21-14 04:30PM  Will BioMarin (BMRN) Disappoint This Earnings Season? Zacks +5.23%
09:29AM  Some Potential Targets for Shire to Buy With $1.6B in Free Money at TheStreet
Oct-14-14 06:09AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
Oct-08-14 08:00AM  BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET GlobeNewswire
Sep-30-14 07:20AM  Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug at TheStreet
Sep-29-14 04:05PM  Catalyst Pharma's lead drug succeeds in late-stage study Reuters
Sep-25-14 05:24PM  BioMarin (BMRN) Faces Threat of Genericization for Kuvan Zacks
08:35AM  5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential at 24/7 Wall St.
Sep-24-14 05:21PM  FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets GlobeNewswire
Sep-23-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
Sep-15-14 08:00AM  BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines GlobeNewswire
Sep-10-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences in London GlobeNewswire
Sep-05-14 04:35PM  Merck KGaA's Kuvan Effective in Under-4 Year Olds Zacks
Sep-03-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
Aug-31-14 03:00AM  Early data suggest Sanofi, Regeneron drug may halve heart risk Reuters
Aug-28-14 01:04PM  NVO, BMRN And ILMN, 3 Health Care Stocks Pushing The Sector Lower at TheStreet
Aug-27-14 04:20PM  BioMarin Cuts '14 Revenue View after Voucher Sale Evaluation Zacks
06:40AM  Can BioMarin Pharmaceutical (BMRN) Run Higher on Strong Earnings Estimate Revisions? Zacks
Aug-26-14 04:21PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Results of Operations and Financial Condition EDGAR Online
Aug-19-14 08:00AM  BioMarin to Present at Upcoming Investor Conferences GlobeNewswire
Aug-14-14 01:32PM  Temasek Adds China Holdings With JD.com, Cheetah Stakes at Bloomberg
Aug-08-14 10:29AM  Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The Wall Street Transcript Wall Street Transcript
Aug-07-14 11:40AM  NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Zacks
07:04AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
Aug-06-14 04:02PM  BioMarin Weathers The Storm Benzinga
Aug-05-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
07:33AM  Saving kids: When unapproved drugs are the only hope at CNBC
Aug-01-14 01:28PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Jul-31-14 04:00PM  BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Zacks
01:34PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-30-14 04:08PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Sells Priority Review Voucher for $67.5 Million GlobeNewswire
04:01PM  BioMarin Announces Second Quarter 2014 Financial Results GlobeNewswire
11:04AM  Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Zacks
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise12.995,00064,95055,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale70.005,000350,00050,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise12.9910,000129,90060,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale67.4110,000674,09650,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Option Exercise12.995,00064,95055,740Jan 06 04:08 PM
FUCHS HENRY JEVP, Chief Medical OfficerJan 02Sale68.9791663,17242,350Jan 06 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Sale68.905,000344,48350,740Jan 06 04:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale68.7110,000687,14350,740Dec 27 12:07 PM